#1
|
|||
|
|||
Ãåìîëèòè÷åñêàÿ àíåìèÿ Ìèíêîâñêîãî-Øîôôàðà
Óâàæàåìûé Âàäèì Âàëåðüåâè÷, çäðàâñòâóéòå! Õîòåëà áû ñïðîñèòü Âàñ âîò î ÷åì: 1. Ñóùåñòâóåò ëè ñïîñîá ïðîäëåíèÿ ðåìèññèè ïîñëå ïåðåëèâàíèÿ ýðèòðîöèòàðíîé ìàññû (óìîì ïîíèìàþ ÷òî âåðîÿòíî ýòî èç îáëàñòè ôàíòàñòèêè íî âñå æå ìîæåò áûòü åñòü ðàáîòû ïî ýòîìó ïîâîäó) 2. Ãäå â Ìîñêâå èëè îáëàñòè ìîæíî ïîëó÷èòü êâàëèôèöèðîâàííóþ ïîìîùü ïî òðàíñôóçèîëîãèè äëÿ ðåáåíêà, êðîìå Ìîðîçîâñêîé áîëüíèöû?
Ðå÷ü èäåò î ìîåì ñûíå 5 ìåñ, äèàãíîç óñòàíîâëåí ìíîé â 1,5 ìåñ. Ïåðåëèâàëèñü óæå 2 ðàçà. Ìíå ñäåëàíà ñïëåíýêòîìèÿ â 4,5 ãîäà ñ òåõ ïîð âñå õîðîøî. Çàðàíåå áëàãîäàðíà çà îòâåò. |
#2
|
||||
|
||||
ïî ïîâîäó ðåáåíêà è òðàíñôóçèé îáÿçàòåëüíî ïðî÷òèòå ýòî (åñëè äèàãíîç 100%):
Hemoglobin values are usually normal at birth but decrease sharply during the subsequent 20 days, which leads, in many cases, to a transient and severe anemia. The anemia is severe enough to warrant blood transfusions in a large number of infants with HS (26 of 34 in our series). The aggravation of anemia appears to be related to the inability of these infants to mount an appropriate erythropoietic response to anemia and to the development of splenic filtering function. These findings indicate that careful monitoring of infants with HS during the first 6 months of life is important for appropriate clinical management. --- Natural history of hereditary spherocytosis during the first year of life [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#3
|
|||
|
|||
Âàäèì Âàëåðüåâè÷, áîëüøîå ñïàñèáî çà èíôîðìàöèþ. Áóäó òðóäèòñÿ íàä ïåðåâîäîì.  ñëó÷àå âîïðîñîâ äëÿ äèñêóññèè, ïîòðåâîæó Âàì âíîâü.
P.S. Äèàãíîç ñîìíåíèÿ íå âûçûâàåò... |
#4
|
|||
|
|||
Âàäèì Âàëåðüåâè÷, çäðàâñòâóéòå! Ñòàòüþ ïðî÷ëà. Âåñüìà îáíàäåæèâàþùå. Î÷åíü áû õîòåëîñü ÷òîáû ê ãîäó, à ëó÷øå ðàíüøå ó ìàëûøà íàñòóïèëà ðåìèññèÿ. Ïîìîæåòå ïîíÿòü êàêîâû åãî øàíñû? Åñëè äàíî:
Ðîäèëñÿ 11.12.13 îò 1 áåðåìåííîñòè, 1 ðîäîâ, âåñ 3400, ðîñò 53, 8/9 ïî Àïãàð. Íà âòîðûå ñóòêè äèàãíîñòèðîâàíà íåîíàòàëüíàÿ æåëòóõà (îáùèé áèëèðóáèí 306, Hb 130)), íàçíà÷åíà ôîòîòåðàïèÿ, ÷åðåç òðîå ñóòîê îáùèé áèëèðóáèí 244, âûïèñàí íà 9-å ñóòêè ñ áèëèðóáèíîì 150 (î íàñëåäñòâåííîì àíàìíåçå ñîîáùåíî íåîíàòîëîãàì, ïðè âûïèñêå çàâåðÿëè, ÷òî ðåáåíîê çäîðîâ).  òå÷åíèå 1 ìåñ íàáëþäàëàñü èêòåðè÷íîñòü ñêëåð è êîæíûõ ïîêðîâîâ, â ïîëèêëèíèêå ïåäèàòð è íåâðîëîã íàçíà÷èëè ôåíîáàðáèòàë äëÿ ñíèæåíèÿ áèëèðóáèíà, ïðè÷èíó æåëòóõè âûÿñíÿòü íèêòî íå ñîáèðàëñÿ.  5 íåäåëü ñàìîñòîÿòåëüíî ñäàëè àíàëèçû êðîâè (ïðèëîæåíèå) è ïîåõàëè ê ãåìàòîëîãó, âûñòàâëåí äèàãíîç: Íàñëåäñòâåííàÿ ãåìîëèòè÷åñêàÿ ìèêðîñôåðîöèòàðíàÿ àíåìèÿ Ìèíêîâñêîãî-Øîôôàðà, ðåêîìåíäîâàíà òðàíñôóçèÿ ýðèòðîìàññû ïðè ñíèæåíèè ãåìîãëîáèí íèæå 70 ã/ë.  âîçðàñòå 1 ìåñ 18 äíåé ãîñïèòàëèçèðîâàí ñ ãåìîëèòè÷åñêèì êðèçîì ñð. ñò òÿæåñòè â ãåìàòîëîãè÷åñêîå îòäåëåíèå (Hb 68 ã/ë) äëÿ òðàíñôóçèè ýðìàññû. Ïîëó÷àåò ôîëèåâóþ êèñëîòó 1 ìã/ñóò, âèòàìèí Å. Ïîâòîðíàÿ ãîñïèòàëèçàöèÿ ÷åðåç 2 ìåñ (Hb 78) ñ ïîâòîðíîé òðàíñôóçèåé ýðìàññû, âûïèñàí 07.04.14 ñ ãåìîãëîáèíîì 125. Ñðàçó ïåðåíåñ âèðóñíóþ èíôåêöèþ, ëå÷åíèå ñèìïòîìàòè÷åñêîå â òå÷åíèå 2 íåä. Äàëåå ãåìîãëîáèí ñíèæàëñÿ ñîãëàñíî òàáëèöå (êîòîðóþ íå ìîãó ïðèêðåïèòü íè â êàêîì ôîðìàòå).  íàñòîÿùåå âðåìÿ Hb 84 (îò 07.06.14), âíîâü ðåøàåòñÿ âîïðîñ î ãîñïèòàëèçàöèè. Ñ óâàæåíèåì, Äàðüÿ |
#5
|
||||
|
||||
ê ñîæàëåíèþ, ëè÷íîãî îïûòà â ýòîì äåëå ó ìåíÿ íåò, êîãäà íîðìàëèçóåòñÿ ýðèòðîïîýç - íåèçâåñòíî, ïîïðîáóéòå íàéòè ñïåöèàëèñòà ñ îïûòîì â ðåàëå, êîòîðûé áû ìîã âåñòè Âàøåãî ðåáåíêà.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#6
|
|||
|
|||
Áóäó èñêàòü!!!
|
#7
|
|||
|
|||
Âàäèì Âàëåðüåâè÷, çäðàâñòâóéòå! Ó ìåíÿ ñòîèò åùå îäíà çàäà÷à- âàêöèíàöèÿ ìàëûøà. Ïîêà ó íàñ òîëüêî ÁÖÆ â ðîääîìå. Ãåìàòîëîãè ñòàöèîíàðà ðåêîìåíäóþò íå ñïåøèòü, â ïîëèêëèíèêå ãåìàòîëîã íàñòàèâàåò íà ïðèâèâêàõ. ß âàêöèíèðîâàòü ïëàíèðóþ, íî òåïåðü íóæåí êàêîé òî èíäèâèäóàëüíûé êàëåíäàðü. Èíòåðåñíî Âàøå ìíåíèå. Åñëè ïîäáðîñèòå ññûëêè íà ðàáîòû, çàðàíåå ñïàñèáî!!!
|
|
#8
|
|||
|
|||
Âàäèì Âàëåðüåâè÷, çäðàâñòâóéòå! Ñíîâà ê Âàì ñ âîïðîñîì.  ïðîøëûé ðàç ïî÷òè ìåñ íàçàä êîãäà Hb áûë 84 ãåìàòîëîã íàçíà÷èëè ïðåäíèçîëîí â äîçå 7,5 ìã íà 7 äíåé íà ýòîì ôîíå Hb ïîäíÿëñÿ äî 94 ã/ë. Ñåãîäíÿ ñïóñòÿ 2 íåä ñíîâà 81 ã/ë êîíå÷íî çàâòðà áóäó ñâÿçûâàòüñÿ ñ ãåìàòîëîãàìè. Åñëè ñíîâà ïðåäëîæàò ïðåäíèçîëîí ñîãëàøàòüñÿ ëè èëè íàñòàèâàòü íà òðàíñôóçèè? È òî ñòðàøíî è äðóãîå.....
|
#9
|
||||
|
||||
ðåçóëüòàòû àíàëèçà êðîâè ïîëíîñòüþ âûëîæèòü ìîæåòå? % ðåòèêóëîöèòîâ äî è ïîñëå ïðåäíèçîëîíà? Íå ðåêîìåíäóåòñÿ î÷åíü äîëãî äàâàòü ñòåðîèäû äåòÿì ñ ìèêðîñôåðîöèòîçîì, åñëè ãåìîãëîáèí íå ñíèæàåòñÿ ìåíåå 70 ã/ë.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#10
|
||||
|
||||
Îáñóäèòå ñ Âàøèì ãåìàòîëîãîì âîò òàêóþ ñòðàòåãèþ:
Hematol J. 2000;1(3):146-52. Recombinant erythropoietin therapy as an alternative to blood transfusions in infants with hereditary spherocytosis. Tchernia G1, Delhommeau F, Perrotta S, Cynober T, Bader-Meunier B, Nobili B, Rohrlich P, Salomon JL, Sagot-Bevenot S, del Giudice EM, Delaunay J, DeMattia D, Schischmanoff PO, Mohandas N, Iolascon A; ESPHI working group on hemolytic anemias. INTRODUCTION: In hereditary spherocytosis, erythropoiesis has been described as 'sluggish' during the first months of life. The lack of appropriate erythropoietic response to compensate for increased red cell destruction necessitates blood transfusions in 70-80% of hereditary spherocytosis-affected infants during their first year of life. After this period, less than 30% require regular transfusion support. This transient requirement for transfusion led us to wonder whether anemic hereditary spherocytosis infants, like anemic premature infants, could benefit from recombinant erythropoietin therapy (rHu-Epo). MATERIAL AND METHODS: In 16 hereditary spherocytosis infants (age range 16-119 days) with severe anemia, a compassionate open preliminary study was performed. rHu-Epo treatment (1000 IU/kg/week) was instituted together with iron supplementation. Hemoglobin values and reticulocyte counts were repeatedly assessed. RESULTS: In 13 out of 16 infants, prompt increases in reticulocyte counts were noted after the first week of treatment with 1000 IU/kg/week of rHu-Epo. During treatment with Epo these infants maintained clinically acceptable levels of hemoglobin and did not require blood transfusions. As the infants grew and began to mount an adequate erythropoietic response, the rHu-Epo dose could be tapered and the treatment could be discontinued before the age of nine months. CONCLUSION: Epo treatment in most hereditary spherocytosis infants appears to be effective in the management of anemia and could serve as a valuable alternative to packed RBC transfusions.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#11
|
||||
|
||||
íåíóæíûå òðàíñôóçèè ýðèòðîìàññû ó äåòåé ñ âðîæäåííûì ìèêðîñôåðîöèòîçîì èíîãäà ìîãóò äàâàòü è ñàìûå íåïðèÿòíûå îñëîæíåíèÿ:
Complications of Evans' syndrome in an infant with hereditary spherocytosis: a case report [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#12
|
||||
|
||||
ýòî èç áðèòàíñêèõ ðåêîìåíäàöèé:
Some neonates with HS may be transfusion-dependent due to their inability to mount an adequate erythropoietic response in the first year of life (Delhommeau, et al 2000). Continued transfusion-dependence is unusual and it is important to avoid repeated transfusion where possible. Erythropoietin may be of benefit in reducing or avoiding transfusion, and can usually be stopped by the age of 9 months (Tchernia, et al 2000). Many older children with Hb levels of 50-60 g/l do not require transfusion. Children requiring one or two transfusions early in life frequently become transfusion independent. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#13
|
|||
|
|||
Âàäèì Âàëåðüåâè÷, ðåçóëüòàòû âûêëàäûâàþ: îò 07.06.14 - ïîñëå ýòîãî 09.06 íà÷àëñÿ ïðåäíèçîëîí 7,5 ìã/ñóò, ñëåäóþùèé àíàëèç â÷åðàøíèé (30.06.14), òàì æå ïðîìåæóòî÷íûå ðåçóëüòàòû îò 16.06.14 ïîñëå ïðåäíèçîëîíà, íî ê ñîæàëåíèþ ðåòèêóëîöèòîâ íåò íèãäå
|
#14
|
|||
|
|||
Âàäèì Âàëåðüåâè÷! Òîëüêî â÷åðà ïåðå÷èòûâàëà áðòèàíñêèå ðåêîìåíäàöèè êîòîðûå Âû ïðèñûëàëè ðàíåå, òîæå çàäóìàëàñü ïðî ýðèòðîïîýòèí, íî âîïðîñ ïðè êàêîì óðîâíå ðåòèêóëîöèòîâ èõ ìîæíî ïðèìåíÿòü? Ýòîé ñòàòüè íåò ïîëíîñòüþ? "Recombinant erythropoietin therapy as an alternative to blood transfusions in infants with hereditary spherocytosis" Çà âñå âðåìÿ ó íàñ åñòü 4 çíà÷åíèÿ ðåòèêóëîöèòîâ, çíà÷åíèÿ 57-48-58 ïðîìèëå, à ãåìîãëîáèí 74-65-78 ã/ë ñîîòâåòñòâåííî. Âîò ÿ è çàäóìàëàñü - ýðèòðîïîýòèí íàø ëè âàðèàíò...
|
#15
|
||||
|
||||
å-ïîåòèí ïðèìåíÿåòñÿ âìåñòî òðàíñôóçèé è ïðè ëþáîì çíà÷åíèè ðåòèêóëîöèòîâ, íî ãåìîãëîáèíå ìåíåå 70, ïðè ãåìîãëîáèíå 80-85 íè òðàíñôóçèè, íè åðèòðîïîåòèí ìîæåò áûòü íå íóæåí
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |